PharmaShots | Incisive News in 3 Shots

Subscribe Now

Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

BMS' Opdivo(nivolumab) Receives the US FDA's Approval for the Adjuvant Treatment of High-Risk Urothelial Carcinoma

August 23, 2021

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

AstraZeneca Collaborates with Junshi to Commercialize Toripalimab in China

March 2, 2021

Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Urothelial Carcinoma

Merck KGaA and Pfizer's Bavencio (avelumab) Receive the US FDA's Approval as a 1L Treatment for Locally Advanced or Metastatic Uro...

July 1, 2020

BeiGene's Tislelizumab Receives NMPA's Priority Review to sNDA for Urothelial Carcinoma in China

BeiGene's Tislelizumab Receives NMPA's Priority Review to sNDA for Urothelial Carcinoma in China

July 8, 2019

Johnson & Johnson's Balversa (erdafitinib) Receives FDA's Approval for Locally Advanced or Metastatic Urothelial Carcinoma with Certain FGFR Genetic Alteration

Johnson & Johnson's Balversa (erdafitinib) Receives FDA's Approval for Locally Advanced or Metastatic Urothelial Carcinoma wit...

April 12, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us